PharmaTech

JUNE 20, 2025

BI’s OpnME platform access aims to enhance Abu Dhabi’s clinical research by providing compounds, networks, and collaboration tools. Abbott’s pact focuses on localizing pharma manufacturing, biosimilar development, and advancing UAE’s digital health initiatives.

Dosage 59

Dosage Drug Development Vaccines Packaging 59

Express Pharma

JUNE 5, 2023

GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.

Drug Development 97

Drug Development Biosimilars Compounding 97

European Pharmaceutical Review

APRIL 3, 2024

As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 This is due to these companies looking to meet to the varied needs of pharmaceutical developers, according to the authors. This is contributing to a more streamlined and efficient approach to drug development, according to the report.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

Together, these strategies are anticipated to boost development processes from pre-clinical to first-in-human clinical trials with quicker transition times. In August, the company announced plans to spin off Sandoz, its generics and biosimilars division , to create a new standalone company.

Biosimilars 52

Biosimilars Compounding Drug Development 52

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. BMB Reports. 2017;50(3):111–6. Premier Consulting [Internet].

Drug Development 103

Drug Development Documentation Labelling Biosimilars 103

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

European Pharmaceutical Review

NOVEMBER 6, 2023

million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 Demand for cell lines “in drug development , vaccine production, and therapeutic research is surging”, setting the market up for significant expansion, Ghosh noted. Total cell line product sales are expected to reach $3,124.4

Biosimilars 105

Biosimilars Compounding Drug Development Vaccines 105

Pharmaceutical Technology

JULY 23, 2008

Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office. That will affect the intellectual property of oncology drug manufacturers.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Compounding Drug Development 40

Express Pharma

JULY 10, 2024

Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” These trends serve as crucial catalysts, necessitating a shift in priorities and a much-needed transformation of the manufacturing sector.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

Pharmaceutical Technology

DECEMBER 9, 2022

Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers. HQ ADDRESS: Römerpark 2.

Vaccines 52

Vaccines Biosimilars Compounding Packaging 52

PharmaShots

APRIL 3, 2023

The P-III trial (GUARD) results showed no safety signals & were found to be well tolerated with no observed treatment-emergent serious AEs ADX-2191 is a sterile, non-compounded IVT formulation of methotrexate for specific rare retinal diseases. It also has a pipeline of drugs under development that incl.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40